Reusable MoS₂ RF Biosensor Enables Cost-Effective Liquid Biopsies for Early Cancer Detection

Why It Matters

By lowering assay cost and offering reusability, the sensor could broaden access to early cancer screening and accelerate adoption of liquid‑biopsy tests in both clinical and consumer settings.

Key Takeaways

• MoS₂ RF sensor detects ssDNA at 154.67 nM
• Reusable up to five cycles without performance loss
• Fabrication uses simple MoS₂ ink, low-cost scalable
• Enables label‑free, non‑invasive liquid biopsy
• Potential for home‑based cancer monitoring devices

Pulse Analysis

The liquid‑biopsy market is projected to exceed $5 billion by 2030, driven by demand for minimally invasive cancer screening. Yet high‑cost, single‑use assays have limited widespread adoption, especially in low‑resource settings. MoS₂, a two‑dimensional semiconductor, offers exceptional surface‑to‑volume ratios and tunable electronic properties, making it ideal for sensitive biosensing platforms. Integrating MoS₂ with radio‑frequency (RF) readout creates a label‑free detection method that translates molecular binding events into measurable frequency shifts, sidestepping expensive reagents and complex optical instrumentation.

Technical advantages of the UNIST‑KAIST‑Yonsei sensor stem from its RF resonator design, which directly monitors permittivity and resistance changes when target DNA binds. This approach yields a detection limit of 154.67 nM for the AluSx1 ssDNA fragment, comparable to laboratory‑grade PCR assays but at a fraction of the cost. The sensor’s wash‑and‑reuse protocol—using complementary DNA strands to release bound targets—preserves performance over five cycles, dramatically reducing per‑test expense. Compared with conventional electrochemical or fluorescence‑based biosensors, the MoS₂ RF device eliminates the need for labeling, simplifies workflow, and supports rapid, on‑chip analysis.

From a business perspective, the technology opens pathways to decentralized diagnostics and home‑health monitoring. Scalable ink‑based printing of MoS₂ layers can be integrated into disposable cartridges or wearable patches, aligning with trends toward point‑of‑care testing and telemedicine. Regulatory clearance will hinge on demonstrating consistent sensitivity and specificity across repeated uses, but the sensor’s low material cost and straightforward manufacturing could accelerate market entry. If adopted broadly, it promises to lower early‑cancer detection costs, improve patient outcomes, and create new revenue streams for med‑tech firms targeting personalized oncology solutions.